Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Lymphoma, T-Cell 2Uveal Melanoma 1Neuroendocrine Tumors 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Immunoblastic Lymphadenopathy 1Eye Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Neuroendocrine 1

Interventions

Nivolumab 3Cisplatin 3atezolizumab 2Irinotecan 2Ipilimumab 2Etoposide 2Carboplatin 2tivozanib 1repotrectinib 1niraparib 1gallium Ga 68 dotatate 1dostarlimab 1cabozantinib 1budigalimab 1belinostat 1Topotecan 1Temozolomide 1Specimen Handling 1Radiosurgery 1Radionuclide Imaging 1Positron-Emission Tomography 1Positron Emission Tomography Computed Tomography 1Magnetic Resonance Spectroscopy 1Leucovorin 1Immunoglobulin G 1IFL protocol 1Fluorouracil 1Disulfides 1DLL3 protein, human 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Neuroendocrine × belinostat × 90 days × Clear all
NCT06406465 2026-06-05

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
60 enrolled
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡